Table 1. Patient characteristics.
|
IC group
|
C group
|
|||
|---|---|---|---|---|
| n | % | n | % | |
| Patients enrolled | 74 | 73 | ||
| Patients eligible and evaluable for response and toxicity | 71 | 96 | 68 | 93 |
| Age (years) | ||||
| Median (range) | 61 (36–77) | 64 (36–78) | ||
| Gender | ||||
| Male | 64 | 90 | 58 | 85 |
| Female | 7 | 10 | 10 | 15 |
| Stage | ||||
| III | — | — | — | — |
| IV | 74 | 100 | 73 | 100 |
| PS (WHO) | ||||
| 0–1 | 58 | 82 | 53 | 78 |
| 2 | 13 | 18 | 15 | 22 |
| Histology | ||||
| Squamous | 26 | 37 | 24 | 35 |
| Adenocarcinoma | 33 | 47 | 33 | 49 |
| Large cell | 1 | 1 | 1 | 1 |
| Undifferentiated | 11 | 15 | 10 | 15 |
| Prior treatment | ||||
| Surgery | 13 | 18 | 9 | 13 |
| Radiotherapy (adjuvant/curative) | 12 | 17 | 11 | 16 |
| Chemotherapy | 74 | 100 | 68 | 100 |
| Line of chemotherapy | ||||
| Second | 68 | 96 | 61 | 90 |
| Third | 3 | 4 | 7 | 10 |
| Objective response to first-line chemotherapy | ||||
| CR | — | — | 1 | 2 |
| PR | 17 | 24 | 22 | 32 |
| SD | 18 | 25 | 26 | 38 |
| PD | 36 | 51 | 19 | 28 |
PS=performance status; WHO=World Health Organisation; CR=complete remission; PR=partial remission; SD=stable disease; PD=progressive disease.